NEW YORK (GenomeWeb News) – Labcyte said today that the Institute for Molecular Medicine Finland, known as FIMM, will use Labcyte's acoustic liquid handling technology in its small molecule-based personalized cancer medicine programs, under a new collaboration.

Helsinki-based FIMM has already used Labcyte's acoustic liquid handling technology to generate better data and to reduce the costs of its small-molecule screening for the past three years, Labcyte CEO Mark Fischer-Colbrie said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.